Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ATOS 
Atossa Genetics Inc (ATOS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ATOS (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.62
1 Year Target Price $5.62
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 77.28% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 113.61M USD | Price to earnings Ratio - | 1Y Target Price 5.62 |
Price to earnings Ratio - | 1Y Target Price 5.62 | ||
Volume (30-day avg) 4 | Beta 0.9 | 52 Weeks Range 0.55 - 1.66 | Updated Date 06/29/2025 |
52 Weeks Range 0.55 - 1.66 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -21.67% | Return on Equity (TTM) -34.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 50077809 | Price to Sales(TTM) - |
Enterprise Value 50077809 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 2.01 | Shares Outstanding 129170000 | Shares Floating 129098960 |
Shares Outstanding 129170000 | Shares Floating 129098960 | ||
Percent Insiders 0.07 | Percent Institutions 26.58 |
Analyst Ratings
Rating 2 | Target Price 5.62 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Atossa Genetics Inc
Company Overview
History and Background
Atossa Therapeutics, Inc. (ATOS) is a clinical-stage biopharmaceutical company. Founded in 2009, it focuses on developing innovative therapies and delivery methods for breast cancer and other breast conditions. Originally focused on diagnostics, the company has shifted its focus to therapeutics.
Core Business Areas
- Breast Cancer Therapeutics: Development of pharmaceutical products for the treatment and prevention of breast cancer, including proprietary formulations of Endoxifen.
- Drug Delivery: Exploring novel drug delivery methods to improve the efficacy and safety of their therapeutics.
Leadership and Structure
Dr. Steven Quay is the President and CEO. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Endoxifen: Atossa's primary product is oral Endoxifen, a selective estrogen receptor modulator (SERM) being developed for the treatment of breast cancer and for reducing mammographic breast density (MBD). Atossa currently does not have FDA approval. The company hopes to compete with Tamoxifen, AstraZeneca (AZN). Atossa does not have significant market share or revenue yet. Market share data is not yet available.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and heavily regulated. It's driven by innovation, clinical trial success, and regulatory approvals. The breast cancer therapeutics market is a significant segment within the pharmaceutical industry, with ongoing research and development for new and improved treatments.
Positioning
Atossa is a clinical-stage company aiming to establish a presence in the breast cancer therapeutics market with Endoxifen. The company's competitive advantage lies in its novel formulation and potential for improved efficacy and safety compared to existing treatments.
Total Addressable Market (TAM)
The global breast cancer therapeutics market size was valued at $24.8 billion in 2023. Atossa is positioned to capture a portion of this market with Endoxifen if it receives regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach with Endoxifen
- Proprietary drug delivery technologies
- Experienced leadership team
- Focus on a significant unmet medical need
Weaknesses
- Clinical-stage company with no approved products
- Reliance on clinical trial success
- Limited financial resources compared to larger pharmaceutical companies
- Concentrated product pipeline
Opportunities
- Positive clinical trial results for Endoxifen
- Partnerships with larger pharmaceutical companies
- Expansion into new breast cancer indications
- Potential for Breakthrough Therapy designation
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from established pharmaceutical companies
- Patent challenges
- Difficulty raising capital
Competitors and Market Share
Key Competitors
- AZN
- PFE
- NVS
Competitive Landscape
Atossa faces significant competition from established pharmaceutical companies with greater resources and approved products. Atossa's competitive advantage is based on its innovative technology and novel drug delivery methods if approved.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily related to R&D activities. There is little or no commercial revenue. Historical growth reflects a clinical-stage company.
Future Projections: Future growth depends on clinical trial success and regulatory approvals. Analyst expectations depend on their ability to succeed.
Recent Initiatives: Focus on progressing Endoxifen through clinical trials, exploring new drug delivery methods, and partnering with other organizations.
Summary
Atossa Therapeutics is a high-risk, high-reward clinical-stage biopharmaceutical company focused on breast cancer therapeutics. The company's success hinges on the clinical trial results and regulatory approval of its Endoxifen. The company needs to secure funding and partnerships to advance its pipeline. While the breast cancer therapeutics market offers substantial potential, Atossa needs to carefully manage its resources and overcome regulatory hurdles to realize that potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Investment in Atossa Therapeutics Inc is speculative and involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Atossa Genetics Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2012-11-08 | Chairman, CEO & President Dr. Steven C. Quay FCAP, M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | |
Full time employees 15 | |||
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.